Case Control Study
Copyright ©The Author(s) 2024.
World J Diabetes. Mar 15, 2024; 15(3): 418-428
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.418
Figure 1
Figure 1 Flow chart of subject selection. MAFLD: Metabolic dysfunction-associated fatty liver disease; FIB-4 index: Fibrosis-4 index.
Figure 2
Figure 2 Predictive value of angiopoietin-like protein 8 and triglyceride-glucose index. A: Predictive value in metabolic dysfunction-associated fatty liver disease; B: Predictive value in liver fibrosis. MAFLD: Metabolic dysfunction-associated fatty liver disease; ANGPTL8: Angiopoietin-like protein 8; TyG index: Triglyceride-glucose index.
Figure 3
Figure 3 Comparison of 3 indexs between the liver fibrosis and non-fibrosis groups. A: Angiopoietin-like protein 8; B: Triglyceride-glucose index levels; C: C-reactive protein. MAFLD: Metabolic dysfunction-associated fatty liver disease; ANGPTL8: Angiopoietin-like protein 8; CRP: C-reactive protein.